Skip to main content

Spyre Therapeutics, Inc. (SYRE) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $70.08: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 6.46; Below-average business quality.

Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases, with four Phase 2 programs: SPY001 (anti-α4β7 for IBD), SPY002 (anti-TL1A for IBD), SPY003 (anti-IL-23 for IBD), and SPY072 (anti-TL1A for... Read more

$70.08+22.3% A.UpsideScore 4.7/10#120 of 157 Biotechnology
QualityF-score2 / 9FCF yield-1.16%
Stop $65.17Target $85.68(analyst − 10%)A.R:R 1.8:1
Analyst target$95.20+35.8%15 analysts
$85.68our TP
$70.08price
$95.20mean
$115

Sell if holding. Engine safety override at $70.08: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 6.46; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val7.5Qual1.2Grw5.0Mom3.1Sent7.8Ins3.4Peer5.0Tech7.5Risk0.74.7OVERALL

Recent Developments — Spyre Therapeutics, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: WuXi Biologics
Quality below floor (1.2 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-24.9
Mkt Cap$6.5B
EV/EBITDA—
Profit Mgn0.0%
ROE-31.1%
Rev Growth—
Beta3.13
DividendNone
Rating analysts23

Quality Signals

Piotroski F2/9

Options Flow

P/C6.46bearish
IV74%elevated

Concentration Risks(10-K Item 1A)

  • HIGHSupplierWuXi Biologics
    10-K Item 1: 'The WuXi Biologics MSA governs certain development activities and Good Manufacturing Practice (“GMP”) manufacturing and testing for the SPY001, SPY002, and SPY003 programs'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Volatile — 6.3% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Put Call
0.0
Beta
0.0
Implied Vol
1.0
Days To Cover
1.2
Short Interest
2.0
High short interest justified: 15%Elevated put/call: 6.46High IV: 74%Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
2.2
Moat
3.8
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
3.0
Rsi
5.5
Ma Position
6.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.1<4.5A.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
53 · Neutral
↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $67.18Resistance $78.80

Price Targets

$65
$86
A.Upside+22.3%
A.R:R1.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.2 < 4.0)
! Momentum score 3.1/10 — below 4.5 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-04 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SYRE stock a buy right now?

Sell if holding. Engine safety override at $70.08: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 6.46; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $65.17. Score 4.7/10, moderate confidence.

What is the SYRE stock price target?

Take-profit target: $85.68 (+22.3% upside). Prior stop was $65.17. Stop-loss: $65.17.

What are the risks of investing in SYRE?

Concentration risk — Supplier: WuXi Biologics; Quality below floor (1.2 < 4.0).

Is SYRE overvalued or undervalued?

Spyre Therapeutics, Inc. trades at a P/E of N/A (forward -24.9). TrendMatrix value score: 7.5/10. Verdict: Sell.

What do analysts say about SYRE?

23 analysts cover SYRE with a consensus score of 4.5/5. Average price target: $95.

What does Spyre Therapeutics, Inc. do?Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and...

Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases, with four Phase 2 programs: SPY001 (anti-α4β7 for IBD), SPY002 (anti-TL1A for IBD), SPY003 (anti-IL-23 for IBD), and SPY072 (anti-TL1A for RA/PsA/axSpA). As of December 31, 2025, Spyre had $756.5 million in cash and no approved products generating revenue.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · ARGX (argenx SE) · HALO (Halozyme Therapeutics, Inc.) · ADMA (ADMA Biologics Inc)